A5035684724- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Renal and related cancers
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Peptidase Inhibition and Analysis
- Protease and Inhibitor Mechanisms
LMU Klinikum
2022-2023
Ludwig-Maximilians-Universität München
2022-2023
[68Ga]Ga-FAPI-46 is a novel positron emission tomography (PET) ligand that targets fibroblast activation protein (FAP) expression as FAP inhibitor (FAPI) and could already show promising results in several tumor entities. It be demonstrated an increased correlates with aggressivity urothelial carcinoma (UC). Given the limited value of [18F]FDG UC, add diagnostic information staging response assessment UC. We present first data PET imaging pilot cohort UC patients evaluating uptake...
In dynamic brain positron emission tomography (PET) studies, acquiring a time series of images, typically lasting more than an hour, is necessary to derive pharmacokinetic parameters. Analytically, these parameters are estimated by establishing kinetic models such as compartment that consist sets ordinary differential equations (ODE), and fitting the sparse time-activity curve (TAC) tracer. Yet, simplified approximations highly complex underlying processes, sufficient samples TAC required...
In renal cell carcinoma (RCC), accurate imaging methods are required for treatment planning and response assessment to therapy. addition, there is an urgent need new therapeutic options, especially in metastatic RCC. One way combine diagnostics therapy a so-called theranostic approach the use of radioligands directed against surface antigens. For instance, prostate-specific membrane antigen (PSMA) have already been successfully used diagnosis radionuclide prostate cancer. Recent studies...